KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Myasthenia Gravis · Generalized Myasthenia Gravis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 66 (planned)
- Started
- Aug 28, 2024
- Main results expected
- Sep 2027
- Fully finished
- Sep 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2)
Measured over: 18 months
Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2)
Measured over: 24 weeks
Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Measured over: 24 weeks
Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm (Phase 3)
Measured over: 24 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06193889 · record last updated 2026-07-29 · checked 2026-11-09 15:47 UTC